Transplantation, AutologousHematopoietic Stem Cell TransplantationStem Cell TransplantationPeripheral Blood Stem Cell TransplantationAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyTreatment OutcomeMultiple MyelomaCyclophosphamideMelphalanTransplantation, HomologousTransplantation ConditioningSalvage TherapyLymphoma, Non-HodgkinRemission InductionStem CellsDisease-Free SurvivalAntineoplastic AgentsEtoposideHodgkin DiseaseMyeloablative AgonistsBone Marrow TransplantationCytarabineRecurrenceCarmustineSurvival RateHematopoietic Stem Cell MobilizationGraft vs Host DiseaseThiotepaBone Marrow PurgingVincristineSurvival AnalysisHematologic NeoplasmsWhole-Body IrradiationLymphoma, Mantle-CellRetrospective StudiesAmyloidosisHematopoietic Stem CellsDoxorubicinBone and BonesBusulfanDexamethasoneBoronic AcidsPrognosisPyrazinesGraft SurvivalFollow-Up StudiesAntibodies, Monoclonal, Murine-DerivedAntineoplastic Agents, AlkylatingLymphoma, FollicularAntigens, CD34AutograftsLymphoma, T-Cell, PeripheralLiver TransplantationThalidomideTime FactorsIfosfamideChemotherapy, AdjuvantInduction ChemotherapyMesenchymal Stem Cell TransplantationGranulocyte Colony-Stimulating FactorLeukapheresisPrednisoneLymphomaPodophyllotoxinTransplantation ChimeraNeoplasm, ResidualLymphoma, Large B-Cell, DiffuseMaintenance ChemotherapyDose-Response Relationship, DrugBone MarrowTissue DonorsLeukemia, Myeloid, AcuteCord Blood Stem Cell TransplantationCell TransplantationKidney TransplantationLymphoma, B-CellMyelodysplastic SyndromesBone Marrow CellsEmbryonic Stem CellsEnteropathy-Associated T-Cell LymphomaMitoxantroneIdarubicinLeukemia, Plasma CellNeoplasms, Second PrimaryInfusions, SpinalCisplatinProspective StudiesCarboplatinDrug Administration ScheduleAdult Stem CellsImmunosuppressive AgentsBlood Component RemovalAntibodies, MonoclonalHistocompatibility TestingNeoplasm Recurrence, LocalCell DifferentiationFeasibility StudiesLeukemia, MyeloidFatal Outcome